Adalimumab
Brand names: Humira Pen, Humira(Cf), Humira(Cf) Pen Crohn's-Uc-Hs, Humira(Cf) Pen Psor-Uv-Adol Hs, Humira, Humira(Cf) Pen
At a glance
- Medicare prescriptions, 2024
- 528,153
- Medicare drug cost
- $4.52B
- Average cost per prescription
- $8,549
- Clinicians who prescribed it
- 13,393
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active r heumatoid a rthritis. Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis. Reducing signs and symptoms in adult patients with active ankylosing spondylitis. Treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. Treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older. Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
From the FDA-approved prescribing information (label dated December 2025). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: SERIOUS INFECTIONS AND MALIGNANCY SERIOUS INFECTIONS Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue HUMIRA if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before HUMIRA use and during therapy. Initiate treatment for latent TB prior to HUMIRA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may…
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Rheumatology 55.7%
- Nurse Practitioners 10.4%
- Gastroenterology 10.2%
- Physician Assistants 9.1%
- Dermatology 7.7%
- Internal Medicine 3.3%
- Family Medicine 1.3%
- Ophthalmology 0.5%
- Allergy & Immunology 0.3%
- Mohs Surgery 0.2%
- Pharmacists 0.2%
- Dermatopathology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 16% from 2019 to 2024.
Biggest change by state since 2019
- Indiana +37%
- Oklahoma +37%
- Mississippi +33%
- Virginia +32%
- Connecticut +31%
- California (smallest change) −4%
- Oregon (smallest change) +1%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $128,191 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- AbbVie Inc. $128,191
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
5 recalls since 2020
- Jan 2026 · Acme United Corporation · Class II
CGMP Deviations - Jul 2025 · Medline Industries, LP - Northfield · Class II
Subpotent Drug- isopropyl alcohol levels fall below the labeled concentration. - Feb 2025 · Medline Industries, LP - Northfield · Class II
Subpotent Drug - Mar 2023 · Focus Health Group Inc · Class III
Labeling; Incorrect NDC number on outer carton of product. - Jun 2022 · McKesson Medical-Surgical Inc. Corporate Office · Class II
CGMP Deviations: products were stored outside the drug label specifications.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Industry-funded trials
- Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis Completed · AbbVie Inc.
- A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) Active, not recruiting · AbbVie Inc.
- A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) Completed · AbbVie Inc.
- Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis Completed · AbbVie Inc.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.